American Journal of Psychiatry and Neuroscience

| Peer-Reviewed |

A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study on the Efficacy of Clonidine in Detoxification of Opioid Dependency

Received: 19 September 2016    Accepted: 09 February 2017    Published: 09 March 2017
Views:       Downloads:

Share This Article

Abstract

Background: Clonidine is α² adrenergic receptor agonist with detrimental effect on locus coeruleus. It is considered as one of the detoxification drugs in order to reduce opiate withdrawal syndrome. We conducted this study in order to assess clonidine effect on withdrawal symptoms and signs. Materials and methods This double blind, clinical trial, single centered study was conducted among 104 male inpatient heroin dependent patients in Psychiatric Center. They were selected via convenient sampling method. Subsequently, they were divided randomly into two matched groups: trial–control (clonidine –placebo) groups. Withdrawal symptoms and signs based on DSM–5 were compared in groups. Results: In 14 day detoxification period (in 7th and 14th day examination), the effect of clonidine on craving and agitation (p < 0.01) was significant. With respect to other symptoms and signs, clonidine was not effective prominently. Discussion: Due to different results compared to previous studies in this area. Clonidine use with respect to opioid withdrawal syndrome needs further evaluation or may need to revise.

DOI 10.11648/j.ajpn.20160406.11
Published in American Journal of Psychiatry and Neuroscience (Volume 4, Issue 6, November 2016)
Page(s) 87-90
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Clonidine, Drug Dependency, Withdrawal Syndrome

References
[1] Grogoretti C, Moglia B, Pelosi P. Clonidine in Preoperative Medicine and Intensive Care Unit more than an Anti – hypertensive Drug. Curr Drug Targets 2009; 10 (8): 799–814.
[2] Kelly P Cosgrov, Jeffery Bati, Feredric Bois. Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry 2009. 66 (6): 666–676.
[3] Esmaeili A, Kennhorst AK, Schuster T. Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. Acta Pediatr 2010. 99 (2): 209–214.
[4] Jenkines LA, Playfor SD, Bevan C. Current Tinted Kingdom sedation practice in pediatric intensive care. Pediatr Anesth 2009. 17 (7): 675–683.
[5] Stroobe S, Brower KJ, Galen LW. Predicting completion of outpatient opioid detoxification with clonidine. Am J Addict 2003. 12 (3): 260–269.
[6] Umricht A, Hoover DR, Tucker JM. Opioid detoxification with buprenorphine and clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug Alcohol Depend 2003. 69 (3): 268–272.
[7] Sobey PW, Parran TV, Grey SF. The use of tramadol for acute heroin withdrawal. J Addict Dis 2003. 22 (4): 13–25.
[8] Feng X, Zhang F, Dong R. Interathecal administration of clonidine attenuates spinal neuroimmune activation in a rat model of neuropathic pain with existing hyperalgesia. Journal Article. Eur J Pharmacol 2009. Apr 24.
[9] Bruijnzeel AW, Bishoni M, Tuijl IA. Effect of prazocin, clonidine and propranolol on the elevations in brain reward threshold and somatic sign associated with nicotine withdrawal in rats. Journal Psychopharmacology 2010; 10.
[10] Ziaadinni H, Quhestani A, Moin Vaziri M. Comparing Symptoms of Wthdrawal Rapid Detoxification and Detoxification with Clonidine in Drug Dependent Patients. Addiction & Health 2009; 1 (2).
[11] Ziaadinni H, Nasirian M, Nakhaei N. A Comparation of the Efficacy of Buprenorphine and Clonidine in Detoxification of Heroin- Dependent and the Following Management treatment. Addiction & Health 2010; 2 (1).
[12] Salehi B, Jafarinia N, Ghebleh F, Mansouri A. A comparative Study on opium Withdrawal of Buprenorphine and clonidine. The Journal of Qazvin University of Medical Science 2007; 11 (3 (44)): 57-64.
[13] Broome L, Tsz- Yin. The Use of Clonidine as a Treatment Option. NEO Reviews 2011; 2 (10): 575-584.
[14] Alexander G. Agthe, George R. Kim, Kay B. Mathis, Craig W. Hendrix, Raul C. Valdez, Laurren Jansson et al. Clonidine as an Adjunct therapy to Opioid for Neonatal Abstinence Syndrome: A Randomized Controlled Trial. Pedeitrics 2009; 123 (5).
[15] Naderi A, Naderi M, Rahmani F, Salimi R, Gleiss A, Kasper S. Ultra- Rapid Detoxification Followed by Nine Month of Naltroxane Maintenance Therapy in Iran. Thieme 2010; 43 (4): 130-137.
[16] Lobmaier P, Gossop M, Waal H, Bramness J. The pharmacological Treatment of Opioid Addiction- a Clinical Prospective. Europian Journal of Clinical Pharmacology 2010; 66 (6): 537-545.
Author Information
  • Department of Psychology, University of Tehran, Tehran, Iran

  • Department of Psychiatry, Psychiatry and Behavioral Science Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Cite This Article
  • APA Style

    Mani B. Monajemi, Seyyed Mohammad Moosavi. (2017). A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study on the Efficacy of Clonidine in Detoxification of Opioid Dependency. American Journal of Psychiatry and Neuroscience, 4(6), 87-90. https://doi.org/10.11648/j.ajpn.20160406.11

    Copy | Download

    ACS Style

    Mani B. Monajemi; Seyyed Mohammad Moosavi. A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study on the Efficacy of Clonidine in Detoxification of Opioid Dependency. Am. J. Psychiatry Neurosci. 2017, 4(6), 87-90. doi: 10.11648/j.ajpn.20160406.11

    Copy | Download

    AMA Style

    Mani B. Monajemi, Seyyed Mohammad Moosavi. A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study on the Efficacy of Clonidine in Detoxification of Opioid Dependency. Am J Psychiatry Neurosci. 2017;4(6):87-90. doi: 10.11648/j.ajpn.20160406.11

    Copy | Download

  • @article{10.11648/j.ajpn.20160406.11,
      author = {Mani B. Monajemi and Seyyed Mohammad Moosavi},
      title = {A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study on the Efficacy of Clonidine in Detoxification of Opioid Dependency},
      journal = {American Journal of Psychiatry and Neuroscience},
      volume = {4},
      number = {6},
      pages = {87-90},
      doi = {10.11648/j.ajpn.20160406.11},
      url = {https://doi.org/10.11648/j.ajpn.20160406.11},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ajpn.20160406.11},
      abstract = {Background: Clonidine is α² adrenergic receptor agonist with detrimental effect on locus coeruleus. It is considered as one of the detoxification drugs in order to reduce opiate withdrawal syndrome. We conducted this study in order to assess clonidine effect on withdrawal symptoms and signs. Materials and methods This double blind, clinical trial, single centered study was conducted among 104 male inpatient heroin dependent patients in Psychiatric Center. They were selected via convenient sampling method. Subsequently, they were divided randomly into two matched groups: trial–control (clonidine –placebo) groups. Withdrawal symptoms and signs based on DSM–5 were compared in groups. Results: In 14 day detoxification period (in 7th and 14th day examination), the effect of clonidine on craving and agitation (p < 0.01) was significant. With respect to other symptoms and signs, clonidine was not effective prominently. Discussion: Due to different results compared to previous studies in this area. Clonidine use with respect to opioid withdrawal syndrome needs further evaluation or may need to revise.},
     year = {2017}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study on the Efficacy of Clonidine in Detoxification of Opioid Dependency
    AU  - Mani B. Monajemi
    AU  - Seyyed Mohammad Moosavi
    Y1  - 2017/03/09
    PY  - 2017
    N1  - https://doi.org/10.11648/j.ajpn.20160406.11
    DO  - 10.11648/j.ajpn.20160406.11
    T2  - American Journal of Psychiatry and Neuroscience
    JF  - American Journal of Psychiatry and Neuroscience
    JO  - American Journal of Psychiatry and Neuroscience
    SP  - 87
    EP  - 90
    PB  - Science Publishing Group
    SN  - 2330-426X
    UR  - https://doi.org/10.11648/j.ajpn.20160406.11
    AB  - Background: Clonidine is α² adrenergic receptor agonist with detrimental effect on locus coeruleus. It is considered as one of the detoxification drugs in order to reduce opiate withdrawal syndrome. We conducted this study in order to assess clonidine effect on withdrawal symptoms and signs. Materials and methods This double blind, clinical trial, single centered study was conducted among 104 male inpatient heroin dependent patients in Psychiatric Center. They were selected via convenient sampling method. Subsequently, they were divided randomly into two matched groups: trial–control (clonidine –placebo) groups. Withdrawal symptoms and signs based on DSM–5 were compared in groups. Results: In 14 day detoxification period (in 7th and 14th day examination), the effect of clonidine on craving and agitation (p < 0.01) was significant. With respect to other symptoms and signs, clonidine was not effective prominently. Discussion: Due to different results compared to previous studies in this area. Clonidine use with respect to opioid withdrawal syndrome needs further evaluation or may need to revise.
    VL  - 4
    IS  - 6
    ER  - 

    Copy | Download

  • Sections